Homology Medicines, Inc. (FIXX) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts FIXX Hot Sheet
Join SI Premium – FREE
Homology Medicines, Inc. (NASDAQ: FIXX) reported Q2 EPS of ($0.61), $0.11 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $354 thousand versus the consensus estimate of $864.4 thousand.
For earnings history and earnings-related data on Homology Medicines, Inc. (FIXX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
- Studio City International Holdings Limited (MSC) Reports Q3 Loss of $0.02
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
